

Table 6.6i
Immunosuppression Use for Antirejection Treatment from Transplant
to One Year Following Transplantation, 1997 to 2006
Recipients with Pancreas Transplant Alone (PTA) Transplants

	Year of Transplant									
	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
Transplants	79	88	139	134	167	181	160	183	199	173
Tx with Antirejection Treatments	22	21	30	28	20	36	31	34	31	23
Antibodies										
Any in Category	68.2%	52.4%	90.0%	92.9%	65.0%	63.9%	77.4%	55.9%	51.6%	39.1%
Atgam/NRATG/NRATS	18.2%	9.5%	0.0%	0.0%	5.0%	0.0%	0.0%	2.9%	0.0%	0.0%
OKT3	59.1%	47.6%	73.3%	57.1%	30.0%	38.9%	25.8%	20.6%	25.8%	21.7%
Thymoglobulin	0.0%	9.5%	40.0%	57.1%	40.0%	36.1%	54.8%	26.5%	35.5%	13.0%
Zenapax	0.0%	0.0%	13.3%	3.6%	5.0%	2.8%	9.7%	2.9%	0.0%	4.3%
Simulect	0.0%	0.0%	3.3%	3.6%	5.0%	0.0%	0.0%	0.0%	0.0%	4.3%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	11.1%	38.7%	26.5%	3.2%	0.0%
Corticosteroids										
Any in Category	63.6%	71.4%	73.3%	78.6%	90.0%	86.1%	80.6%	85.3%	83.9%	95.7%
Steroids	63.6%	71.4%	73.3%	78.6%	90.0%	86.1%	80.6%	85.3%	83.9%	95.7%
Antimetabolites										
Any in Category	4.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Methotrexate	4.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 1, 2008.

Notes:

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.